Vedolizumab

Category: Gastrointestinal

Vedolizumab, sold under the brand name Entyvio, is a monoclonal antibody medication developed by Millennium Pharmaceuticals, Inc. for the treatment of ulcerative colitis and Crohn's disease.[3] It binds to integrin α4β7 (LPAM-1, lymphocyte Peyer's patch adhesion molecule 1, a dimer of Integrin alpha-4 and Integrin beta-7).[3][4] Blocking the α4β7 integrin results in gut-selective anti-inflammatory activity.[5]... [wikipedia]

Dosage List

Entyvio Pen 108 mg/.68ml Subcutaneous Injection, Solution
NDC: 64764-108
Labeler:
Takeda Pharmaceuticals America, Inc.

Related Brands

Drugs with the same active ingredients